Please login to the form below

Not currently logged in
Email:
Password:

AD04

This page shows the latest AD04 news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer’s failure as Targacept trial disappoints

Another Alzheimer’s failure as Targacept trial disappoints

This June the UK's Medical Research Council (MRC) launched a £16m dementia research programme and Austrian biopharma company AFFiRiS claimed its drug candidate AD04 was the first therapy to show

Latest news

  • Burden of proof Burden of proof

    Breakthroughs in Alzheimer's are sorely needed, but there's still lots of work to do on AD04. ... So a wait-and-see approach remains prudent - only further, rigorous testing will tell if AD04 really is a breakthrough.

  • AFFiRiS claims a first in Alzheimer's disease therapy AFFiRiS claims a first in Alzheimer's disease therapy

    AD04 a peptide-based vaccine targeting beta amyloid, the material that makes up the characteristic amyloid plaques found in the brains of Alzheimer's patients. ... AD02 will now take a back seat while the company places more emphasis on AD04's development

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics